ClinVar Miner

Submissions for variant NM_000179.2(MSH6):c.1844G>T (p.Cys615Phe) (rs730881793)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000165560 SCV000216293 uncertain significance Hereditary cancer-predisposing syndrome 2017-09-12 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Insufficient or conflicting evidence
Invitae RCV000168072 SCV000218726 uncertain significance Hereditary nonpolyposis colon cancer 2018-11-07 criteria provided, single submitter clinical testing This sequence change replaces cysteine with phenylalanine at codon 615 of the MSH6 protein (p.Cys615Phe). The cysteine residue is weakly conserved and there is a large physicochemical difference between cysteine and phenylalanine. This variant is not present in population databases (ExAC no frequency). This variant has been reported in individuals affected with colorectal cancer (PMID: 28135145). ClinVar contains an entry for this variant (Variation ID: 186038). Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
GeneDx RCV000479956 SCV000565218 uncertain significance not provided 2018-12-26 criteria provided, single submitter clinical testing This variant is denoted MSH6 c.1844G>T at the cDNA level, p.Cys615Phe (C615F) at the protein level, and results in the change of a Cysteine to a Phenylalanine (TGT>TTT). This variant has been observed in at least two individuals with colorectal cancer as well as in a cohort of patients with advanced cancer (Mandelker 2017, Yurgelun 2017). MSH6 Cys615Phe was observed at an allele frequency of 0.02% (2/8,730) in individuals of African ancestry in large population cohorts (Lek 2016). This variant is located in the connector domain (Warren 2007, Kasikas 2011). In-silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function. Based on currently available evidence, it is unclear whether MSH6 Cys615Phe is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Color RCV000165560 SCV000690226 uncertain significance Hereditary cancer-predisposing syndrome 2018-08-24 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.